Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 12Not yet recruiting 4Active not recruiting 3Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Metastatic Adenocarcinoma of the Pancreas 1

Interventions

pembrolizumab 68Cyclophosphamide 46Cisplatin 43Nivolumab 36Paclitaxel 33Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Bevacizumab 20Doxorubicin 19Magnetic Resonance Spectroscopy 18Blood Specimen Collection 18Radiosurgery 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Letrozole 15Ipilimumab 15Fluorouracil 15palbociclib 14Surveys and Questionnaires 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14durvalumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × irinotecan sucrosofate × 90 days × Clear all
NCT04083235 2026-04-20

NAPOLI 3

Ipsen

Phase 3 Completed
770 enrolled 13 charts 1 FDA
Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡